December 10, 2019. The benefit Vernakalant for rapid conversion of recent-onset Afib might possibly provide to a subset of patients does not outweigh the serious risks associated with it.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
NCHR Comments on Abuse Deterrent Formulations for Stimulant Medications
November 19, 2019. If FDA approves abuse deterrent formulations, the label should clearly describe the exact property demonstrated in studies.
Read More »NCHR’s Comments on the Safer Technologies Program (STeP) for Medical Devices
November 18, 2019. We therefore respectfully urge the FDA to revise the proposed guidance in ways that ensure that all medical devices undergo more rigorous testing prior to being approved or cleared.
Read More »NCHR Testimony on Research Needed on Immunological Responses to Metal in Implants
November 13, 2019. Dr. Diana Zuckerman describes the types of research needed to reduce harm from the metal and other substances in implanted devices, including joint replacements, cardiac implants, mesh, reproductive devices, and many other types of implants.
Read More »NCHR Testimony on Empagliflozin to Improve Glycemic Control
November 13, 2019. The data on Empagliflozin for managing Type 1 Diabetes is limited and it is not clear if the small improvement seen in the clinical trial is clinically meaningful for patients.
Read More »